Educational background:

2014.09—2019.12        City University of Hong Kong, Doctor of Philosophy

2011.09—2014.07        Chengdu Institute of Organic Chemistry—CAS, Master of Organic Chemistry

2007.09—2011.07        Jilin Univesity, Bachelor of Chemistry  

Work experience:

2024.08—Now             SUSTech, Research Assistant Professor

2021.09—2024.07        Shenzhen Bay Laboratory, Assistant Researcher

2020.01—2021.07        University of Arizona, Postdoctoral Associate   

Research Area：

Organic Chemistry, Coordination Chemistry, and Medicinal Chemistry

Publications：

1. Xu, Zoufeng†; Sung, Y.†; Tomat, E., Design of tetrazolium cations for the release of antiproliferative formazan chelators in mammalian cells. Journal of the American Chemical Society, 2023, 145, 15197-15206. https://doi.org/10.1021/jacs.3c02033

2. Xu, Zoufeng†; Lin L.†; Fu B.; Huang F.; Zhou Q.; Zhu G.; Wang, Z., Ligand substitution reactions afford oxaliplatin-based platinum(IV) complexes bearing axial alkoxido ligands. Inorganic Chemistry Frontiers, 2023. 10, 6058-6066. https://doi.org/10.1039/D3QI01562A

3. Xu, Zoufeng; Wang, Z.; Deng, Z.; Zhu, G., Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs. Coordination Chemistry Reviews, 2021, 442, 213991. https://doi.org/10.1016/j.ccr.2021.213991

4. Xu, Zoufeng; Tang, W. K.; Zhou, Q.; Chen, S.; Siu, C.-K.; Zhu, G., On the hydrolytic stability of unsymmetric platinum(IV) anticancer prodrugs containing axial halogens. Inorganic Chemistry Frontiers, 2021, 8, 3794-3802. https://doi.org/10.1039/D1QI00208B

5. Xu, Zoufeng†; Li, C.†; Zhou, Q.; Deng, Z.; Tong, Z.; Tse, M.-K.; Zhu, G., Synthesis, cytotoxicity, and mechanistic investigation of platinum(IV) anticancer complexes conjugated with poly(ADP-ribose) polymerase inhibitors. Inorganic Chemistry, 2019, 58, 16279-16291. https://doi.org/10.1021/acs.inorgchem.9b02839

6. Xu, Zoufeng; Chan, H. M.; Li, C.; Wang, Z.; Tse, M.-K.; Tong, Z.; Zhu, G., Synthesis, structure, and cytotoxicity of oxaliplatin-based platinum(IV) anticancer prodrugs bearing one axial fluoride. Inorganic Chemistry, 2018, 57, 8227-8235. https://doi.org/10.1021/acs.inorgchem.8b00706

7. Xu, Zoufeng; Li, C.; Tong, Z.; Ma, L.; Tse, M.-K.; Zhu, G., Halogenated PtIV complexes from N-halosuccinimide oxidation of PtII antitumor drugs: synthesis, mechanistic investigation, and cytotoxicity. European Journal of Inorganic Chemistry, 2017, 2017, 1706-1712. https://doi.org/10.1002/ejic.201601130

8. Xu, Zoufeng; Wang, Z.; Yiu, S.-M.; Zhu, G., Mono- and di-bromo platinum(iv) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity. Dalton Transactions, 2015, 44, 19918-19926. https://doi.org/10.1039/C5DT03101J

Patent：

1. Tomat E., Xu Zoufeng, and Sung Y.-S., (2024) Tetrazolium and formazan compounds and methods of making and using the same. Patent No.: WO2024035831A1

2. Zhu G., Xu Zoufeng, and Zhou Q., (2024) Platinum complex, its preparation and therapeutic use. Patent No.: US20210371441A1

3.Zhu G., Wang Z., and Xu Zoufeng, (2021) Platinum complex, its preparation and therapeutic use. Patent No.: US10899781B2

4. Xun X., Ge G., Xu Zoufeng (2015) A synthetic method for cis-2-fluorocyclopropylamine. CN Patent, CN 

106146319 A